Flexion Therapeutics, Inc.
If you purchased Flexion Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
FLEXION MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF FLEXION THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – FLXN
October 11, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDAQ: FLXN) to Pacira BioSciences, Inc. for $8.50 per share in cash, plus one non-tradeable contingent value right worth up to $8.00 per share in cash is fair to Flexion shareholders.
The investigation concerns whether Flexion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Flexion shareholders; (2) determine whether Pacira is underpaying for Flexion; and (3) disclose all material information necessary for Flexion shareholders to adequately assess and value the merger consideration. On behalf of Flexion shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.